Back

Urine γ-interferon-inducible protein (IP-10) as a biomarker of histological activity of lupus nephritis

Prasopsanti, K.; Supasiri, T.; Avihingsanon, Y.; Iampenkhae, K.; Surintrspanont, J.; Chongpisan, Y.; Promjean, C.; Suttichet, T. B.; Assawasaksakul, T.; Oudomying, N.; Kittanamongkolchai, W.

2022-08-17 nephrology
10.1101/2022.08.16.22278832
Show abstract

IntroductionConventional markers are not reliable predictors of histological activity of lupus nephritis (LN). We aimed to examine the utility of urine {gamma}-interferon-inducible protein (IP-10) in predicting LN flares, diagnosis of LN, and forecasting treatment response. MethodsSLE patients who fulfilled the ACR 1997 criteria with history of LN were enrolled. Urine IP-10 was measured at least once during routine quarterly visits, at the time of diagnosis of active LN, and monthly during induction therapy for 6 months. ResultsThere were 65 active LN and 46 inactive LN included. The mean urine IP-10 levels among the active and inactive LN were 2.69 (95%CI 2.53-2.86) and 2.18 (95%CI 1.96-2.39) log copies/mcg total RNA respectively (p-value < 0.0001). Clinicopathological discordance was observed in 9 of 55 (16%) biopsied patients (5 with proliferative LN without proteinuric flare and 4 with nephrotic-range proteinuria from glomerulosclerosis). Urine IP-10 predicted histological activity of LN with 91% accuracy, compared to 84% with proteinuric flare. Within two years, half of the clinically inactive LN patients with positive baseline urine IP-10 developed LN flare, whereas no flares were observed in patients with negative baseline urine IP-10. Urine IP-10 levels were not associated with treatment response at 6 months. ConclusionUrine IP-10 may reflect histological activity of LN more accurately than conventional markers, especially in patients with clinicopathologic discrepancy. Clinically inactive LN patients with positive urine IP-10 were at a higher risk of developing LN flare. Key messages- The majority of the studies on novel biomarkers in LN lacked renal biopsy and relied on clinical indicators to determine histological activity. As a result, the validity of these studies may be jeopardized. - According to this study, clinicopathological discordance was found in 16% of LN patients who underwent renal biopsy. Urine IP-10 outperformed urinary protein level in differentiating histologically active LN from inactive LN (accuracy 91% versus 84%). - Within two years, half of the clinically inactive LN patients who had positive urine IP-10 developed LN flares, whereas none of those who had negative urine IP-10 did. - Urine IP-10 may aid in the diagnosis of histologically active LN, particularly in patients with clinicopathologic discrepancy. Urine IP-10 monitoring in clinically inactive LN patients may predict the risk of future LN flares.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Kidney International
based on 11 papers
Top 0.1%
18.3%
2
Kidney360
based on 14 papers
Top 0.2%
13.5%
3
Kidney International Reports
based on 11 papers
Top 0.2%
11.9%
4
PLOS ONE
based on 1737 papers
Top 60%
6.9%
50% of probability mass above
5
Journal of Clinical Medicine
based on 77 papers
Top 2%
5.0%
6
BMC Nephrology
based on 12 papers
Top 0.6%
3.2%
7
Journal for ImmunoTherapy of Cancer
based on 14 papers
Top 0.6%
3.0%
8
American Journal of Transplantation
based on 13 papers
Top 0.3%
3.0%
9
Scientific Reports
based on 701 papers
Top 58%
2.6%
10
Journal of the American Society of Nephrology
based on 19 papers
Top 0.7%
2.5%
11
Wellcome Open Research
based on 34 papers
Top 1%
1.9%
12
BMC Medicine
based on 155 papers
Top 12%
1.7%
13
JAMA Network Open
based on 125 papers
Top 12%
1.4%
14
International Journal of Medical Informatics
based on 25 papers
Top 4%
1.3%
15
Diagnostics
based on 36 papers
Top 4%
1.3%
16
BioMed Research International
based on 11 papers
Top 2%
1.3%
17
PLOS Neglected Tropical Diseases
based on 166 papers
Top 9%
1.3%
18
JCI Insight
based on 63 papers
Top 5%
0.9%
19
British Journal of Cancer
based on 22 papers
Top 3%
0.9%
20
Annals of the Rheumatic Diseases
based on 23 papers
Top 1%
0.9%
21
Rheumatology
based on 21 papers
Top 0.8%
0.9%
22
Nature Communications
based on 483 papers
Top 39%
0.9%
23
BMC Infectious Diseases
based on 110 papers
Top 16%
0.9%
24
Transplantation
based on 11 papers
Top 0.3%
0.9%
25
Frontiers in Pharmacology
based on 27 papers
Top 4%
0.7%
26
Health Science Reports
based on 11 papers
Top 0.9%
0.7%
27
Emerging Infectious Diseases
based on 84 papers
Top 12%
0.7%
28
Medicine
based on 29 papers
Top 8%
0.7%